Identifying biomarkers for IBD diagnosis and management
Driving biomarker discovery is key as proteomics emerges as the next frontier in precision medicine.
Identifying biomarkers for IBD siagnosis and management
In this webinar, you’ll hear how proteomics technology can enhance the identification of biomarkers for the accurate diagnosis of Crohn’s disease and ulcerative colitis, as well as the identification of biomarkers that predict response to TNF inhibitors and other biologics in patients with IBD.
This webinar will explore how reliable, non-invasive proteomic biomarkers are pivotal for personalized treatment and increasing our knowledge of biological pathways involved in disease. Our expert speaker will also present an assay platform that can measure 11,000 biologically relevant proteins in the search for biomarkers.
Attend this webinar to:
- Explore the role of biomarkers in tailoring medical care and enhancing precision in pediatric IBD treatment
- Uncover serum proteins intricately linked to TNF inhibitor response, gaining insights for improved therapeutic decision-making in IBD
- Discover how the SomaScan® 11K Assay transforms non-invasive biomarker discovery, revolutionizing differential pediatric IBD diagnosis
Towia A. Libermann, PhD
Associate Professor, Medicine, Harvard Medical School
Assistant Professor of Medicine, Division of Interdisciplinary Medicine and Biotechnology, Beth Israel Deaconess Medical Center
Director of BIDMC Genomics, Proteomics, Bioinformatics and Systems Biology Center
Towia A. Libermann, Ph.D. is an Associate Professor of Medicine in the Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School. Dr. Libermann is also the Director of the Beth Israel Deaconess Medical Center Genomics, Proteomics, Bioinformatics and Systems Center and of the Dana Farmer/Harvard Cancer Center Cancer Proteomics Core. Dr. Libermann is an internationally recognized translational investigator with a strong track record in precision medicine, biomarker discovery and translational studies of immunological diseases and cancer. Dr. Libermann’s lab is focused on applying multi-omics approaches to identify proteins or genes that may be exploited as biomarkers or targets for therapeutic intervention, starting with his seminal discovery of EGF receptor gene amplifications in glioblastomas. Dr. Libermann has been at the forefront of the next generation of proteomics and plays a central role in driving biomarker discovery to the next level. Libermann’s group uses the aptamer-based SomaScan proteomics platform, a modified aptamer-based high multiplex immunoassay platform, to discover and validate diagnostic, predictive, and prognostic biomarkers for various diseases using liquid biopsies such as extracellular vesicles and body fluids. Using the latest in machine learning, Libermann’s group has developed predictor models for applications in early detection, disease diagnosis, prediction of therapeutic response, monitoring of disease progression, and outcome prediction. Dr. Libermann received his PhD in Immunology in 1986 from the Weizmann Institute of Science and Technology, Rehovot and did a postdoctoral fellowship at the Whitehead Institute, Cambridge.
Identifying biomarkers for IBD diagnosis and mnagement
A presentation by Towia Libermann, PhD
More webinars
WebinarDetecting growing tumors through changes in the plasma proteome
In this GEN webinar, Nebojsa Janjic, PhD, will discuss the need for a reliable blood-based screening method capable of detecting cancers earlier. During the webinar, he will highlight results from a study involving researchers from SomaLogic and the University of Colorado School of Medicine that used a test capable of measuring 5000 proteins simultaneously.
WebinarBoutique Webinar : Predicting Pregnancy Complications with High-Plex Proteomics
The interdisciplinary team, comprising 10-15 scientists and clinician-scientists, is dedicated to advancing diagnostics and therapeutics aimed at enhancing maternal and fetal care. Their primary focus lies in the development of interventions for conditions such as ectopic pregnancy and preeclampsia, alongside the creation of diagnostics to prevent stillbirth.
WebinarYoung blood for old brains and the quest to slow brain aging
Aging leads to the degradation of function in nearly all tissues and organs. This process is marked by significant shifts in gene expression and changes in concentrations of all types of biological molecules. Recent technological progress has allowed biologists to measure an unprecedented number of these molecules throughout an organism